A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Deuruxolitinib in Healthy Adults

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of deuruxolitinib in healthy adults. This investigation is clinically relevant to determine the initial safety profile and drug behavior of the compound prior to therapeutic application in patients with alopecia areata.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both males and females. The subjects belong to an age group categorized by the code 3 and include vulnerable populations. There are no mentions of specific alopecia areata conditions, lifestyle factors, or detailed selection processes in the provided data.

This Phase 3, double-blind, placebo-controlled, randomized, multiple rising dose study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of deuruxolitinib in healthy adults. The research methodology involves a structured sequence of study visits beginning with a screening visit to assess eligibility. Subsequent visits are conducted to monitor the physiological effects and pharmacological profile of the investigational product. The study concludes with an end-of-study visit. The total duration of the trial is estimated to span from September 2025 to September 2026. Conditions leading to early termination from the study are not specified.

The assessment of efficacy in this phase 3 clinical trial involves evaluating the clinical response in patients with alopecia areata. The specific parameters for determining therapeutic effectiveness are not defined in the provided documentation.